Lonza Group AG | 633.9200 / +0.44% |
Date/Time | 03/01 / 21:54 |
Chg. / Chg.(%) | 2.7900 / +0.44% |
Bid | - |
Ask | - |
Open | 632.5000 |
Previous Close | 631.1300 |
High | 633.9200 |
Low | 632.0000 |
Volume [USD] | 22,782.8320 |
Volume [Units] | 36 |
Price fixings | 6 |
ISIN | CH0013841017 |
Security | LZAGF |
Exchange | Nasdaq Other OTC |
Type | Stock |
Other Exchanges
Exchange | Last | Volume | |
---|---|---|---|
SIX Swiss Ex.. | 575.60 | ![]() |
229,696 |
London Inter.. | 576.05 | ![]() |
18,784 |
Cboe Europe .. | 576.20 | ![]() |
16,825 |
Cboe Europe .. | 575.60 | ![]() |
15,524 |
Turquoise | 576.00 | ![]() |
5,282 |
Nasdaq Other.. | 633.9200 | ![]() |
36 |
Lang & Schwa.. | 522.800 | ![]() |
|
Mexico | 13,449.09 | ![]() |
290 |
TradeGate | 294.000 | 298 | |
Frankfurt | 293.9000 | 63 | |
Düsseldorf | 291.20 | 0 | |
München | 291.30 | 0 | |
Berlin | 296.90 | 0 | |
Hamburg | 291.30 | 0 | |
gettex | 296.100 | ||
Singapore | 79.97 | 500 | |
EUREX | Options |
News
- Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications
01/12/2021 / 15:05 - GlobeNewswire - Achilles Therapeutics Appoints Arjan Roozen as VP, Site Head and General Manager
01/08/2021 / 13:00 - GlobeNewswire - Arbor Biotechnologies and Lonza Enter into Gene Editing Technology Licensing Deal
12/23/2020 / 14:00 - GlobeNewswire - Altimmune Adds Lonza as a Manufacturing Partner for Supply of AdCOVID™ its Single-Dose Intranasal Vaccine Candidate for COVID-19
11/10/2020 / 07:00 - GlobeNewswire - Institutional Investor Research Publishes 2020 Europe Executive Team Rankings
09/04/2020 / 07:00 - GlobeNewswire